Last reviewed · How we verify

NCT04408105: SCREEN-BE

Survey Study on Barrett's Esophagus Screening

Completed Last updated 22 October 2025
What this trial tests

trial testing Primary Care Provider Survey in Gastroesophageal Reflux Disease in 725 participants. Completed in 1 October 2025.

Timeline
19 February 2020
Primary endpoint
23 September 2021
1 October 2025

Quick facts

Lead sponsorUniversity of Colorado, Denver
StatusCompleted
Study typeOBSERVATIONAL
Enrollment725
Start date19 February 2020
Primary completion23 September 2021
Estimated completion1 October 2025
Sites7 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 99, any sex, with Gastroesophageal Reflux Disease or Barrett's Esophagus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to optimize Barrett's Esophagus (BE) screening to reduce the incidence, morbidity, and mortality of Esophageal Adenocarcinoma (EAC).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Patient Knowledge, Risk Perception, and Barriers to Barrett's Esophagus Screening.
    Kolb JM, Chen M, Tavakkoli A, Gallegos J, et al · · 2023 · cited 16× · PMID 36219171 · DOI 10.14309/ajg.0000000000002054
  2. Understanding Compliance, Practice Patterns, and Barriers Among Gastroenterologists and Primary Care Providers Is Crucial for Developing Strategies to Improve Screening for Barrett's Esophagus.
    Kolb JM, Chen M, Tavakkoli A, Singal AG, et al · · 2022 · cited 13× · PMID 35150724 · DOI 10.1053/j.gastro.2022.02.003

Verify or expand the search:

Other recruiting trials for Gastroesophageal Reflux Disease

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04408105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing